nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—NR1H4—connective tissue—systemic scleroderma	0.0133	0.131	CbGeAlD
Fulvestrant—NR1H4—digestive system—systemic scleroderma	0.00958	0.0946	CbGeAlD
Fulvestrant—ESR1—blood vessel—systemic scleroderma	0.00814	0.0803	CbGeAlD
Fulvestrant—EPHX2—tendon—systemic scleroderma	0.00797	0.0787	CbGeAlD
Fulvestrant—ESRRA—digestive system—systemic scleroderma	0.00734	0.0724	CbGeAlD
Fulvestrant—EPHX2—lung—systemic scleroderma	0.00699	0.069	CbGeAlD
Fulvestrant—ESRRA—tendon—systemic scleroderma	0.00698	0.0689	CbGeAlD
Fulvestrant—ESRRA—lung—systemic scleroderma	0.00613	0.0605	CbGeAlD
Fulvestrant—ESR2—connective tissue—systemic scleroderma	0.0061	0.0602	CbGeAlD
Fulvestrant—ESR2—smooth muscle tissue—systemic scleroderma	0.00558	0.055	CbGeAlD
Fulvestrant—ESR2—digestive system—systemic scleroderma	0.0044	0.0434	CbGeAlD
Fulvestrant—ESR1—connective tissue—systemic scleroderma	0.00417	0.0412	CbGeAlD
Fulvestrant—ESR1—smooth muscle tissue—systemic scleroderma	0.00382	0.0377	CbGeAlD
Fulvestrant—ESR2—lung—systemic scleroderma	0.00368	0.0363	CbGeAlD
Fulvestrant—ESR1—digestive system—systemic scleroderma	0.00302	0.0298	CbGeAlD
Fulvestrant—ESR1—lung—systemic scleroderma	0.00252	0.0248	CbGeAlD
Fulvestrant—ESR1—FOXM1 transcription factor network—CENPB—systemic scleroderma	0.00243	0.15	CbGpPWpGaD
Fulvestrant—CYP3A4—digestive system—systemic scleroderma	0.00168	0.0166	CbGeAlD
Fulvestrant—Angioedema—Lisinopril—systemic scleroderma	0.00154	0.00175	CcSEcCtD
Fulvestrant—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.00154	0.00174	CcSEcCtD
Fulvestrant—Abdominal pain—Captopril—systemic scleroderma	0.00154	0.00174	CcSEcCtD
Fulvestrant—Body temperature increased—Captopril—systemic scleroderma	0.00154	0.00174	CcSEcCtD
Fulvestrant—Anorexia—Leflunomide—systemic scleroderma	0.00153	0.00173	CcSEcCtD
Fulvestrant—Nausea—Pentoxifylline—systemic scleroderma	0.00152	0.00173	CcSEcCtD
Fulvestrant—Infection—Mycophenolic acid—systemic scleroderma	0.00152	0.00172	CcSEcCtD
Fulvestrant—Vertigo—Lisinopril—systemic scleroderma	0.00151	0.00172	CcSEcCtD
Fulvestrant—Diarrhoea—Mometasone—systemic scleroderma	0.00151	0.00171	CcSEcCtD
Fulvestrant—Leukopenia—Lisinopril—systemic scleroderma	0.00151	0.00171	CcSEcCtD
Fulvestrant—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.0015	0.0017	CcSEcCtD
Fulvestrant—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00148	0.00168	CcSEcCtD
Fulvestrant—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.00148	0.00167	CcSEcCtD
Fulvestrant—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00148	0.00167	CcSEcCtD
Fulvestrant—Cough—Lisinopril—systemic scleroderma	0.00147	0.00167	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00146	0.00166	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00146	0.00165	CcSEcCtD
Fulvestrant—Anorexia—Mycophenolic acid—systemic scleroderma	0.00146	0.00165	CcSEcCtD
Fulvestrant—Insomnia—Leflunomide—systemic scleroderma	0.00145	0.00164	CcSEcCtD
Fulvestrant—Paraesthesia—Leflunomide—systemic scleroderma	0.00144	0.00163	CcSEcCtD
Fulvestrant—Arthralgia—Lisinopril—systemic scleroderma	0.00143	0.00163	CcSEcCtD
Fulvestrant—Myalgia—Lisinopril—systemic scleroderma	0.00143	0.00163	CcSEcCtD
Fulvestrant—Chest pain—Lisinopril—systemic scleroderma	0.00143	0.00163	CcSEcCtD
Fulvestrant—Anxiety—Lisinopril—systemic scleroderma	0.00143	0.00162	CcSEcCtD
Fulvestrant—Back pain—Mycophenolate mofetil—systemic scleroderma	0.00143	0.00162	CcSEcCtD
Fulvestrant—Dyspnoea—Leflunomide—systemic scleroderma	0.00143	0.00162	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00143	0.00161	CcSEcCtD
Fulvestrant—Dyspepsia—Leflunomide—systemic scleroderma	0.00141	0.0016	CcSEcCtD
Fulvestrant—Vomiting—Mometasone—systemic scleroderma	0.00141	0.00159	CcSEcCtD
Fulvestrant—Rash—Mometasone—systemic scleroderma	0.00139	0.00158	CcSEcCtD
Fulvestrant—Asthenia—Captopril—systemic scleroderma	0.00139	0.00158	CcSEcCtD
Fulvestrant—Dermatitis—Mometasone—systemic scleroderma	0.00139	0.00158	CcSEcCtD
Fulvestrant—Decreased appetite—Leflunomide—systemic scleroderma	0.00139	0.00158	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00139	0.00158	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00139	0.00157	CcSEcCtD
Fulvestrant—Headache—Mometasone—systemic scleroderma	0.00139	0.00157	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00138	0.00157	CcSEcCtD
Fulvestrant—Insomnia—Mycophenolic acid—systemic scleroderma	0.00138	0.00157	CcSEcCtD
Fulvestrant—Fatigue—Leflunomide—systemic scleroderma	0.00138	0.00156	CcSEcCtD
Fulvestrant—Pruritus—Captopril—systemic scleroderma	0.00137	0.00156	CcSEcCtD
Fulvestrant—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.00137	0.00155	CcSEcCtD
Fulvestrant—Pain—Leflunomide—systemic scleroderma	0.00137	0.00155	CcSEcCtD
Fulvestrant—Constipation—Leflunomide—systemic scleroderma	0.00137	0.00155	CcSEcCtD
Fulvestrant—Infection—Lisinopril—systemic scleroderma	0.00137	0.00155	CcSEcCtD
Fulvestrant—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.00136	0.00155	CcSEcCtD
Fulvestrant—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00136	0.00154	CcSEcCtD
Fulvestrant—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.00135	0.00153	CcSEcCtD
Fulvestrant—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00134	0.00152	CcSEcCtD
Fulvestrant—Abdominal pain—Azathioprine—systemic scleroderma	0.00134	0.00152	CcSEcCtD
Fulvestrant—Body temperature increased—Azathioprine—systemic scleroderma	0.00134	0.00152	CcSEcCtD
Fulvestrant—Skin disorder—Lisinopril—systemic scleroderma	0.00134	0.00151	CcSEcCtD
Fulvestrant—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00133	0.00151	CcSEcCtD
Fulvestrant—Diarrhoea—Captopril—systemic scleroderma	0.00133	0.00151	CcSEcCtD
Fulvestrant—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00133	0.0015	CcSEcCtD
Fulvestrant—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.00133	0.0015	CcSEcCtD
Fulvestrant—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00132	0.0015	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00132	0.00149	CcSEcCtD
Fulvestrant—Fatigue—Mycophenolic acid—systemic scleroderma	0.00132	0.00149	CcSEcCtD
Fulvestrant—Nausea—Mometasone—systemic scleroderma	0.00131	0.00149	CcSEcCtD
Fulvestrant—Anorexia—Lisinopril—systemic scleroderma	0.00131	0.00149	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00131	0.00148	CcSEcCtD
Fulvestrant—Pain—Mycophenolic acid—systemic scleroderma	0.00131	0.00148	CcSEcCtD
Fulvestrant—Constipation—Mycophenolic acid—systemic scleroderma	0.00131	0.00148	CcSEcCtD
Fulvestrant—Cough—Mycophenolate mofetil—systemic scleroderma	0.00129	0.00146	CcSEcCtD
Fulvestrant—Dizziness—Captopril—systemic scleroderma	0.00128	0.00146	CcSEcCtD
Fulvestrant—Depression—Prednisone—systemic scleroderma	0.00128	0.00145	CcSEcCtD
Fulvestrant—Urticaria—Leflunomide—systemic scleroderma	0.00127	0.00144	CcSEcCtD
Fulvestrant—Abdominal pain—Leflunomide—systemic scleroderma	0.00127	0.00143	CcSEcCtD
Fulvestrant—Body temperature increased—Leflunomide—systemic scleroderma	0.00127	0.00143	CcSEcCtD
Fulvestrant—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00142	CcSEcCtD
Fulvestrant—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00142	CcSEcCtD
Fulvestrant—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00142	CcSEcCtD
Fulvestrant—Breast disorder—Methotrexate—systemic scleroderma	0.00126	0.00142	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00125	0.00142	CcSEcCtD
Fulvestrant—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00142	CcSEcCtD
Fulvestrant—Hypersensitivity—Azathioprine—systemic scleroderma	0.00125	0.00142	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00125	0.00142	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00141	CcSEcCtD
Fulvestrant—Insomnia—Lisinopril—systemic scleroderma	0.00124	0.00141	CcSEcCtD
Fulvestrant—Paraesthesia—Lisinopril—systemic scleroderma	0.00124	0.0014	CcSEcCtD
Fulvestrant—Vomiting—Captopril—systemic scleroderma	0.00123	0.0014	CcSEcCtD
Fulvestrant—Dyspnoea—Lisinopril—systemic scleroderma	0.00123	0.00139	CcSEcCtD
Fulvestrant—Rash—Captopril—systemic scleroderma	0.00122	0.00139	CcSEcCtD
Fulvestrant—Dermatitis—Captopril—systemic scleroderma	0.00122	0.00139	CcSEcCtD
Fulvestrant—Headache—Captopril—systemic scleroderma	0.00122	0.00138	CcSEcCtD
Fulvestrant—Dyspepsia—Lisinopril—systemic scleroderma	0.00121	0.00137	CcSEcCtD
Fulvestrant—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00121	0.00137	CcSEcCtD
Fulvestrant—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00121	0.00137	CcSEcCtD
Fulvestrant—Infection—Mycophenolate mofetil—systemic scleroderma	0.0012	0.00136	CcSEcCtD
Fulvestrant—Decreased appetite—Lisinopril—systemic scleroderma	0.0012	0.00136	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00119	0.00135	CcSEcCtD
Fulvestrant—Fatigue—Lisinopril—systemic scleroderma	0.00119	0.00134	CcSEcCtD
Fulvestrant—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00118	0.00134	CcSEcCtD
Fulvestrant—Hypersensitivity—Leflunomide—systemic scleroderma	0.00118	0.00134	CcSEcCtD
Fulvestrant—Pain—Lisinopril—systemic scleroderma	0.00118	0.00133	CcSEcCtD
Fulvestrant—Constipation—Lisinopril—systemic scleroderma	0.00118	0.00133	CcSEcCtD
Fulvestrant—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00117	0.00133	CcSEcCtD
Fulvestrant—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00117	0.00132	CcSEcCtD
Fulvestrant—Diarrhoea—Azathioprine—systemic scleroderma	0.00116	0.00131	CcSEcCtD
Fulvestrant—Haemoglobin—Prednisone—systemic scleroderma	0.00116	0.00131	CcSEcCtD
Fulvestrant—Nausea—Captopril—systemic scleroderma	0.00115	0.00131	CcSEcCtD
Fulvestrant—Haemorrhage—Prednisone—systemic scleroderma	0.00115	0.0013	CcSEcCtD
Fulvestrant—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00115	0.0013	CcSEcCtD
Fulvestrant—Asthenia—Leflunomide—systemic scleroderma	0.00115	0.0013	CcSEcCtD
Fulvestrant—Pruritus—Leflunomide—systemic scleroderma	0.00113	0.00128	CcSEcCtD
Fulvestrant—Connective tissue disorder—Prednisone—systemic scleroderma	0.00113	0.00128	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00112	0.00127	CcSEcCtD
Fulvestrant—Dizziness—Azathioprine—systemic scleroderma	0.00112	0.00127	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.0011	0.00124	CcSEcCtD
Fulvestrant—Asthenia—Mycophenolic acid—systemic scleroderma	0.0011	0.00124	CcSEcCtD
Fulvestrant—Diarrhoea—Leflunomide—systemic scleroderma	0.0011	0.00124	CcSEcCtD
Fulvestrant—Urticaria—Lisinopril—systemic scleroderma	0.00109	0.00124	CcSEcCtD
Fulvestrant—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00109	0.00124	CcSEcCtD
Fulvestrant—Abdominal pain—Lisinopril—systemic scleroderma	0.00109	0.00123	CcSEcCtD
Fulvestrant—Body temperature increased—Lisinopril—systemic scleroderma	0.00109	0.00123	CcSEcCtD
Fulvestrant—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00108	0.00123	CcSEcCtD
Fulvestrant—Pruritus—Mycophenolic acid—systemic scleroderma	0.00108	0.00122	CcSEcCtD
Fulvestrant—Vomiting—Azathioprine—systemic scleroderma	0.00108	0.00122	CcSEcCtD
Fulvestrant—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00107	0.00122	CcSEcCtD
Fulvestrant—Infestation—Methotrexate—systemic scleroderma	0.00107	0.00121	CcSEcCtD
Fulvestrant—Infestation NOS—Methotrexate—systemic scleroderma	0.00107	0.00121	CcSEcCtD
Fulvestrant—Rash—Azathioprine—systemic scleroderma	0.00107	0.00121	CcSEcCtD
Fulvestrant—Dermatitis—Azathioprine—systemic scleroderma	0.00107	0.00121	CcSEcCtD
Fulvestrant—Depression—Methotrexate—systemic scleroderma	0.00107	0.00121	CcSEcCtD
Fulvestrant—Headache—Azathioprine—systemic scleroderma	0.00106	0.0012	CcSEcCtD
Fulvestrant—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00106	0.0012	CcSEcCtD
Fulvestrant—Dizziness—Leflunomide—systemic scleroderma	0.00106	0.0012	CcSEcCtD
Fulvestrant—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00119	CcSEcCtD
Fulvestrant—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00104	0.00118	CcSEcCtD
Fulvestrant—Angiopathy—Prednisone—systemic scleroderma	0.00104	0.00118	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00104	0.00118	CcSEcCtD
Fulvestrant—Immune system disorder—Prednisone—systemic scleroderma	0.00104	0.00118	CcSEcCtD
Fulvestrant—Pain—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00117	CcSEcCtD
Fulvestrant—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00117	CcSEcCtD
Fulvestrant—Sweating—Methotrexate—systemic scleroderma	0.00103	0.00116	CcSEcCtD
Fulvestrant—Vomiting—Leflunomide—systemic scleroderma	0.00102	0.00115	CcSEcCtD
Fulvestrant—Hypersensitivity—Lisinopril—systemic scleroderma	0.00101	0.00115	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.00101	0.00115	CcSEcCtD
Fulvestrant—Dizziness—Mycophenolic acid—systemic scleroderma	0.00101	0.00114	CcSEcCtD
Fulvestrant—Rash—Leflunomide—systemic scleroderma	0.00101	0.00114	CcSEcCtD
Fulvestrant—Dermatitis—Leflunomide—systemic scleroderma	0.00101	0.00114	CcSEcCtD
Fulvestrant—Nausea—Azathioprine—systemic scleroderma	0.00101	0.00114	CcSEcCtD
Fulvestrant—Headache—Leflunomide—systemic scleroderma	0.001	0.00114	CcSEcCtD
Fulvestrant—Malnutrition—Prednisone—systemic scleroderma	0.001	0.00113	CcSEcCtD
Fulvestrant—Asthenia—Lisinopril—systemic scleroderma	0.000987	0.00112	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000986	0.00112	CcSEcCtD
Fulvestrant—Pruritus—Lisinopril—systemic scleroderma	0.000973	0.0011	CcSEcCtD
Fulvestrant—Vomiting—Mycophenolic acid—systemic scleroderma	0.000971	0.0011	CcSEcCtD
Fulvestrant—Haemoglobin—Methotrexate—systemic scleroderma	0.000966	0.00109	CcSEcCtD
Fulvestrant—Rash—Mycophenolic acid—systemic scleroderma	0.000963	0.00109	CcSEcCtD
Fulvestrant—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000962	0.00109	CcSEcCtD
Fulvestrant—Haemorrhage—Methotrexate—systemic scleroderma	0.000961	0.00109	CcSEcCtD
Fulvestrant—Hepatitis—Methotrexate—systemic scleroderma	0.000961	0.00109	CcSEcCtD
Fulvestrant—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000957	0.00108	CcSEcCtD
Fulvestrant—Headache—Mycophenolic acid—systemic scleroderma	0.000957	0.00108	CcSEcCtD
Fulvestrant—Pharyngitis—Methotrexate—systemic scleroderma	0.000954	0.00108	CcSEcCtD
Fulvestrant—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000953	0.00108	CcSEcCtD
Fulvestrant—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000953	0.00108	CcSEcCtD
Fulvestrant—Nausea—Leflunomide—systemic scleroderma	0.000951	0.00108	CcSEcCtD
Fulvestrant—Diarrhoea—Lisinopril—systemic scleroderma	0.000941	0.00107	CcSEcCtD
Fulvestrant—Anaemia—Prednisone—systemic scleroderma	0.000925	0.00105	CcSEcCtD
Fulvestrant—Angioedema—Prednisone—systemic scleroderma	0.000915	0.00104	CcSEcCtD
Fulvestrant—Dizziness—Lisinopril—systemic scleroderma	0.00091	0.00103	CcSEcCtD
Fulvestrant—Nausea—Mycophenolic acid—systemic scleroderma	0.000907	0.00103	CcSEcCtD
Fulvestrant—Vertigo—Prednisone—systemic scleroderma	0.000899	0.00102	CcSEcCtD
Fulvestrant—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000888	0.00101	CcSEcCtD
Fulvestrant—Vomiting—Lisinopril—systemic scleroderma	0.000875	0.000991	CcSEcCtD
Fulvestrant—Angiopathy—Methotrexate—systemic scleroderma	0.000872	0.000988	CcSEcCtD
Fulvestrant—Immune system disorder—Methotrexate—systemic scleroderma	0.000868	0.000984	CcSEcCtD
Fulvestrant—Rash—Lisinopril—systemic scleroderma	0.000867	0.000983	CcSEcCtD
Fulvestrant—Dermatitis—Lisinopril—systemic scleroderma	0.000866	0.000982	CcSEcCtD
Fulvestrant—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000865	0.00098	CcSEcCtD
Fulvestrant—Headache—Lisinopril—systemic scleroderma	0.000862	0.000977	CcSEcCtD
Fulvestrant—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000853	0.000966	CcSEcCtD
Fulvestrant—Myalgia—Prednisone—systemic scleroderma	0.000852	0.000966	CcSEcCtD
Fulvestrant—Arthralgia—Prednisone—systemic scleroderma	0.000852	0.000966	CcSEcCtD
Fulvestrant—Anxiety—Prednisone—systemic scleroderma	0.000849	0.000962	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000846	0.000959	CcSEcCtD
Fulvestrant—Malnutrition—Methotrexate—systemic scleroderma	0.000837	0.000948	CcSEcCtD
Fulvestrant—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000825	0.000934	CcSEcCtD
Fulvestrant—Nausea—Lisinopril—systemic scleroderma	0.000817	0.000926	CcSEcCtD
Fulvestrant—Infection—Prednisone—systemic scleroderma	0.000812	0.00092	CcSEcCtD
Fulvestrant—Back pain—Methotrexate—systemic scleroderma	0.000809	0.000917	CcSEcCtD
Fulvestrant—Nervous system disorder—Prednisone—systemic scleroderma	0.000801	0.000908	CcSEcCtD
Fulvestrant—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000797	0.000903	CcSEcCtD
Fulvestrant—Skin disorder—Prednisone—systemic scleroderma	0.000794	0.000899	CcSEcCtD
Fulvestrant—Hyperhidrosis—Prednisone—systemic scleroderma	0.00079	0.000895	CcSEcCtD
Fulvestrant—Anorexia—Prednisone—systemic scleroderma	0.000779	0.000882	CcSEcCtD
Fulvestrant—Anaemia—Methotrexate—systemic scleroderma	0.000773	0.000876	CcSEcCtD
Fulvestrant—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000766	0.000868	CcSEcCtD
Fulvestrant—Rash—Mycophenolate mofetil—systemic scleroderma	0.00076	0.000861	CcSEcCtD
Fulvestrant—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000759	0.00086	CcSEcCtD
Fulvestrant—Headache—Mycophenolate mofetil—systemic scleroderma	0.000755	0.000856	CcSEcCtD
Fulvestrant—Vertigo—Methotrexate—systemic scleroderma	0.000752	0.000852	CcSEcCtD
Fulvestrant—Leukopenia—Methotrexate—systemic scleroderma	0.000749	0.000849	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000744	0.000843	CcSEcCtD
Fulvestrant—Insomnia—Prednisone—systemic scleroderma	0.000739	0.000837	CcSEcCtD
Fulvestrant—Paraesthesia—Prednisone—systemic scleroderma	0.000734	0.000831	CcSEcCtD
Fulvestrant—Cough—Methotrexate—systemic scleroderma	0.00073	0.000827	CcSEcCtD
Fulvestrant—Dyspepsia—Prednisone—systemic scleroderma	0.000719	0.000815	CcSEcCtD
Fulvestrant—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000716	0.000811	CcSEcCtD
Fulvestrant—Arthralgia—Methotrexate—systemic scleroderma	0.000712	0.000807	CcSEcCtD
Fulvestrant—Chest pain—Methotrexate—systemic scleroderma	0.000712	0.000807	CcSEcCtD
Fulvestrant—Myalgia—Methotrexate—systemic scleroderma	0.000712	0.000807	CcSEcCtD
Fulvestrant—Decreased appetite—Prednisone—systemic scleroderma	0.00071	0.000805	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000707	0.000802	CcSEcCtD
Fulvestrant—Fatigue—Prednisone—systemic scleroderma	0.000704	0.000798	CcSEcCtD
Fulvestrant—Constipation—Prednisone—systemic scleroderma	0.000699	0.000792	CcSEcCtD
Fulvestrant—Infection—Methotrexate—systemic scleroderma	0.000678	0.000769	CcSEcCtD
Fulvestrant—Nervous system disorder—Methotrexate—systemic scleroderma	0.00067	0.000759	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000668	0.000757	CcSEcCtD
Fulvestrant—Skin disorder—Methotrexate—systemic scleroderma	0.000663	0.000752	CcSEcCtD
Fulvestrant—Hyperhidrosis—Methotrexate—systemic scleroderma	0.00066	0.000748	CcSEcCtD
Fulvestrant—Anorexia—Methotrexate—systemic scleroderma	0.000651	0.000737	CcSEcCtD
Fulvestrant—Urticaria—Prednisone—systemic scleroderma	0.000649	0.000735	CcSEcCtD
Fulvestrant—Abdominal pain—Prednisone—systemic scleroderma	0.000646	0.000732	CcSEcCtD
Fulvestrant—Body temperature increased—Prednisone—systemic scleroderma	0.000646	0.000732	CcSEcCtD
Fulvestrant—ESR1—FOXM1 transcription factor network—CENPA—systemic scleroderma	0.000641	0.0396	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000622	0.000705	CcSEcCtD
Fulvestrant—Insomnia—Methotrexate—systemic scleroderma	0.000618	0.0007	CcSEcCtD
Fulvestrant—Paraesthesia—Methotrexate—systemic scleroderma	0.000613	0.000695	CcSEcCtD
Fulvestrant—Dyspnoea—Methotrexate—systemic scleroderma	0.000609	0.00069	CcSEcCtD
Fulvestrant—Hypersensitivity—Prednisone—systemic scleroderma	0.000602	0.000682	CcSEcCtD
Fulvestrant—Dyspepsia—Methotrexate—systemic scleroderma	0.000601	0.000681	CcSEcCtD
Fulvestrant—Decreased appetite—Methotrexate—systemic scleroderma	0.000594	0.000673	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000589	0.000668	CcSEcCtD
Fulvestrant—Fatigue—Methotrexate—systemic scleroderma	0.000589	0.000667	CcSEcCtD
Fulvestrant—Asthenia—Prednisone—systemic scleroderma	0.000586	0.000664	CcSEcCtD
Fulvestrant—ESRRA—PPARA activates gene expression—CTGF—systemic scleroderma	0.000585	0.0361	CbGpPWpGaD
Fulvestrant—Pain—Methotrexate—systemic scleroderma	0.000584	0.000662	CcSEcCtD
Fulvestrant—Pruritus—Prednisone—systemic scleroderma	0.000578	0.000655	CcSEcCtD
Fulvestrant—ESRRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—systemic scleroderma	0.000573	0.0353	CbGpPWpGaD
Fulvestrant—Diarrhoea—Prednisone—systemic scleroderma	0.000559	0.000633	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000558	0.000633	CcSEcCtD
Fulvestrant—Urticaria—Methotrexate—systemic scleroderma	0.000542	0.000615	CcSEcCtD
Fulvestrant—Dizziness—Prednisone—systemic scleroderma	0.00054	0.000612	CcSEcCtD
Fulvestrant—Abdominal pain—Methotrexate—systemic scleroderma	0.00054	0.000612	CcSEcCtD
Fulvestrant—Body temperature increased—Methotrexate—systemic scleroderma	0.00054	0.000612	CcSEcCtD
Fulvestrant—Vomiting—Prednisone—systemic scleroderma	0.000519	0.000589	CcSEcCtD
Fulvestrant—Rash—Prednisone—systemic scleroderma	0.000515	0.000584	CcSEcCtD
Fulvestrant—Dermatitis—Prednisone—systemic scleroderma	0.000515	0.000583	CcSEcCtD
Fulvestrant—Headache—Prednisone—systemic scleroderma	0.000512	0.00058	CcSEcCtD
Fulvestrant—Hypersensitivity—Methotrexate—systemic scleroderma	0.000503	0.00057	CcSEcCtD
Fulvestrant—Asthenia—Methotrexate—systemic scleroderma	0.00049	0.000555	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000486	0.03	CbGpPWpGaD
Fulvestrant—Nausea—Prednisone—systemic scleroderma	0.000485	0.00055	CcSEcCtD
Fulvestrant—Pruritus—Methotrexate—systemic scleroderma	0.000483	0.000547	CcSEcCtD
Fulvestrant—Diarrhoea—Methotrexate—systemic scleroderma	0.000467	0.000529	CcSEcCtD
Fulvestrant—Dizziness—Methotrexate—systemic scleroderma	0.000451	0.000512	CcSEcCtD
Fulvestrant—Vomiting—Methotrexate—systemic scleroderma	0.000434	0.000492	CcSEcCtD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—SMAD7—systemic scleroderma	0.000434	0.0268	CbGpPWpGaD
Fulvestrant—Rash—Methotrexate—systemic scleroderma	0.00043	0.000488	CcSEcCtD
Fulvestrant—Dermatitis—Methotrexate—systemic scleroderma	0.00043	0.000487	CcSEcCtD
Fulvestrant—Headache—Methotrexate—systemic scleroderma	0.000428	0.000485	CcSEcCtD
Fulvestrant—NR1H4—PPARA activates gene expression—CTGF—systemic scleroderma	0.000427	0.0264	CbGpPWpGaD
Fulvestrant—NR1H4—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—systemic scleroderma	0.000418	0.0258	CbGpPWpGaD
Fulvestrant—Nausea—Methotrexate—systemic scleroderma	0.000406	0.00046	CcSEcCtD
Fulvestrant—ESRRA—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—systemic scleroderma	0.000394	0.0243	CbGpPWpGaD
Fulvestrant—NR1H4—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—systemic scleroderma	0.00039	0.0241	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—MMP2—systemic scleroderma	0.000381	0.0235	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—NOS3—systemic scleroderma	0.000357	0.022	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—COL1A2—systemic scleroderma	0.000356	0.0219	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—SMAD7—systemic scleroderma	0.000338	0.0209	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000318	0.0196	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—COL1A2—systemic scleroderma	0.000316	0.0195	CbGpPWpGaD
Fulvestrant—NR1H4—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—systemic scleroderma	0.000288	0.0178	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—MMP9—systemic scleroderma	0.000286	0.0177	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000264	0.0163	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000259	0.016	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—SMAD7—systemic scleroderma	0.000247	0.0152	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000245	0.0151	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—SMAD7—systemic scleroderma	0.000215	0.0133	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000207	0.0128	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.0002	0.0123	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000197	0.0121	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—EDN1—systemic scleroderma	0.000193	0.0119	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—MMP2—systemic scleroderma	0.000192	0.0119	CbGpPWpGaD
Fulvestrant—ESR1—FOXM1 transcription factor network—MMP2—systemic scleroderma	0.000188	0.0116	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—CTGF—systemic scleroderma	0.000187	0.0115	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—NOS3—systemic scleroderma	0.00018	0.0111	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—SMAD7—systemic scleroderma	0.000163	0.01	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—MMP1—systemic scleroderma	0.000162	0.00998	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000157	0.00969	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000151	0.00935	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—TNFSF13—systemic scleroderma	0.000151	0.00933	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—MMP9—systemic scleroderma	0.000144	0.00891	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—MMP2—systemic scleroderma	0.000144	0.00886	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—CTGF—systemic scleroderma	0.000137	0.00843	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—CCL2—systemic scleroderma	0.000132	0.00812	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—SMAD7—systemic scleroderma	0.000119	0.00734	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—CTGF—systemic scleroderma	0.000119	0.00734	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—HSPG2—systemic scleroderma	0.000115	0.00712	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000115	0.00708	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—NOS3—systemic scleroderma	0.000111	0.00685	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—TNFSF13—systemic scleroderma	0.000111	0.00682	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—SMAD7—systemic scleroderma	0.000108	0.00669	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000104	0.00643	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—SMAD7—systemic scleroderma	0.000104	0.00639	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—TNFSF13—systemic scleroderma	9.63e-05	0.00594	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—IL1B—systemic scleroderma	9.45e-05	0.00583	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—MMP9—systemic scleroderma	9.41e-05	0.00581	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—HSPG2—systemic scleroderma	9.23e-05	0.0057	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—CTGF—systemic scleroderma	9e-05	0.00555	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CTGF—systemic scleroderma	8.75e-05	0.0054	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	8.75e-05	0.0054	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—TGFB1—systemic scleroderma	7.94e-05	0.0049	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—TGFB1—systemic scleroderma	7.76e-05	0.00479	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CTGF—systemic scleroderma	7e-05	0.00432	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	6.89e-05	0.00425	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—HSPG2—systemic scleroderma	6.75e-05	0.00416	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—CTGF—systemic scleroderma	6.58e-05	0.00406	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—CTGF—systemic scleroderma	6e-05	0.0037	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—CTGF—systemic scleroderma	5.73e-05	0.00353	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—SMAD7—systemic scleroderma	5.22e-05	0.00322	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CTGF—systemic scleroderma	5.11e-05	0.00315	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—TNFSF13—systemic scleroderma	4.86e-05	0.003	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—NOS3—systemic scleroderma	3.81e-05	0.00235	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.47e-05	0.00214	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SMAD7—systemic scleroderma	3.4e-05	0.0021	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—NOS3—systemic scleroderma	3.05e-05	0.00188	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—CTGF—systemic scleroderma	2.89e-05	0.00178	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—RHOB—systemic scleroderma	2.63e-05	0.00162	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HSPG2—systemic scleroderma	2.48e-05	0.00153	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CSK—systemic scleroderma	2.39e-05	0.00148	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—NOS3—systemic scleroderma	2.23e-05	0.00137	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—EDN1—systemic scleroderma	1.34e-05	0.000827	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—HSPG2—systemic scleroderma	9.66e-06	0.000596	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCL2—systemic scleroderma	9.17e-06	0.000566	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NOS3—systemic scleroderma	8.17e-06	0.000504	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CTGF—systemic scleroderma	7.32e-06	0.000452	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MMP9—systemic scleroderma	6.56e-06	0.000404	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TGFB1—systemic scleroderma	5.4e-06	0.000333	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NOS3—systemic scleroderma	3.19e-06	0.000197	CbGpPWpGaD
